EFFICACY OF CHECKPOINT INHIBITOR IMMUNOTHERAPY DRUG PEMBROLIZUMAB (KEYTRUDA) FOR TREATMENT OF ADVANCED CERVICAL CANCER

被引：0

作者：

Ahmed, F. ^{[1
]}

Shah, Z. ^{[2
]}

Khan, I. ^{[1
]}

Bhatnagar, A. ^{[1
]}

Garimella, R. ^{[1
]}

Mishra, S. ^{[1
]}

Gudapati, S. ^{[3
]}

Bobba, S. H. ^{[3
]}

Zaidi, S. ^{[4
]}

Andrews, K. ^{[5
]}

Salman, U. ^{[6
]}

Yukselen, Z. ^{[1
]}

Guntipalli, P. ^{[1
]}

Zarrar, R. ^{[7
]}

Nya, G. Enebong ^{[8
]}

Ahmad, S. ^{[9
]}

机构：

[1] Larkin Community Hosp, Div Clin & Translat Res, South Miami, FL USA

[2] Weiss Mem Hosp, Dept Internal Med, Chicago, IL USA

[3] Washington Univ Hlth & Sci, Coll Med, San Pedro, Belize

[4] Lahore Med & Dent Coll, Coll Med, Lahore, Pakistan

[5] Prince Mohammad Bin Fahad Univ, Dept CORE, Al Khobar, Saudi Arabia

[6] Bakhtawar Amin Med & Dent Coll, Coll Med, Multan, Pakistan

[7] Mayo Clin, Dept Oncol, Rochester, MN USA

[8] Johns Hopkins Univ Hosp, Dept Gynecol Oncol, Baltimore, MD USA

[9] Advent Hlth Canc Inst, Div Gynecol Oncol, Orlando, FL USA

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2021年 / 31卷

关键词：

D O I：

10.1136/ijgc-2021-ESGO.43

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

567

引用

页码：A32 / A32

页数：1

共 50 条

[31] Prognosis Factors in Advanced Lung Cancer Patients Treated With Checkpoint Inhibitor-Based Immunotherapy
Wu, K.
Zhang, M.
Zhu, L.
Wang, B.
Xia, B.
Ma, S.
Chen, X.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1081 - S1082
[32] Pembrolizumab in the treatment of advanced urothelial cancer
Lundgren, Kevin T.
Farina, Matthew S.
Bellmunt, Joaquim
FUTURE ONCOLOGY, 2017, 13 (30) : 2745 - 2758
[33] Pembrolizumab for the treatment of advanced esophageal cancer
Harada, Kentaro
Yamamoto, Shun
Kato, Ken
FUTURE ONCOLOGY, 2022, 18 (18) : 2311 - 2319
[34] Neurological complications of immune checkpoint inhibitor cancer immunotherapy
Zivelonghi, Cecilia
Zekeridou, Anastasia
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 424
[35] Neurologic Autoimmunity in the Era of Checkpoint Inhibitor Cancer Immunotherapy
Zekeridou, Anastasia
Lennon, Vanda A.
MAYO CLINIC PROCEEDINGS, 2019, 94 (09) : 1865 - 1878
[36] Autoimmune Polyarthritis Induced by Cancer Immunotherapy With Checkpoint Inhibitor
Quresh, Quretul
Quinet, Robert
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2017, 23 (04) : 235 - 235
[37] Apixaban/pembrolizumab/rivaroxabanImmune checkpoint inhibitor-related myocarditis and lack of efficacy
Reactions Weekly, 2024, 2003 (1) : 121 - 121
[38] Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data
Yoo, Seong-Keun
Fitzgerald, Conall W.
Cho, Byuri Angela
Fitzgerald, Bailey G.
Han, Catherine
Koh, Elizabeth S.
Pandey, Abhinav
Sfreddo, Hannah
Crowley, Fionnuala
Korostin, Michelle Rudshteyn
Debnath, Neha
Leyfman, Yan
Valero, Cristina
Lee, Mark
Vos, Joris L.
Lee, Andrew Sangho
Zhao, Karena
Lam, Stanley
Olumuyide, Ezekiel
Kuo, Fengshen
Wilson, Eric A.
Hamon, Pauline
Hennequin, Clotilde
Saffern, Miriam
Vuong, Lynda
Hakimi, A. Ari
Brown, Brian
Merad, Miriam
Gnjatic, Sacha
Bhardwaj, Nina
Galsky, Matthew D.
Schadt, Eric E.
Samstein, Robert M.
Marron, Thomas U.
Goenen, Mithat
Morris, Luc G. T.
Chowell, Diego
NATURE MEDICINE, 2025, : 869 - 880
[39] y Cochrane Rapid Review: The Immune Checkpoint Inhibitor Pembrolizumab versus Chemotherapy for the Treatment of advanced Urothelial Carcinoma
Wilborn, D.
Schmidt, S.
UROLOGE, 2019, 58 (01): : 45 - 48
[40] Effect of body mass index on immune checkpoint inhibitor efficacy in patients with advanced cancer
Sen, Gulin Alkan
Oztas, Nihan Senturk
Degerli, Ezgi
Guliyev, Murad
Turna, Hande
Ozguroglu, Mustafa
TUMORI JOURNAL, 2024,

← 1 2 3 4 5 →